The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1434
Sofosbuvir (Sovaldi) for Chronic Hepatitis C
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the nucleotide polymerase inhibitor sofosbuvir (Sovaldi – Gilead) for use in combination with other antiviral drugs for treatment of chronic hepatitis C virus (HCV) infection.

ACTIVITY — Sofosbuvir is a uridine nucleotide analog prodrug that is converted to an active metabolite in the liver. It inhibits the HCV NS5B RNA-dependent RNA polymerase, which is essential for viral replication. In vitro, sofosbuvir has potent activity against all HCV genotypes (1-6), including strains resistant to protease inhibitors. The prevalence of HCV genotypes in the US is 79% genotype 1, 13% genotype 2, 6% genotype 3, and 2% genotypes 4, 5, and 6 combined.

STANDARD THERAPY — The current standard of care for patients with HCV genotype 1 infection is peginterferon and ribavirin plus a protease inhibitor such as telaprevir (Incivek), boceprevir ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Sofosbuvir (Sovaldi) for Chronic Hepatitis C
Article code: 1434a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian